Back to top
more

Myriad Genetics (MYGN)

(Real Time Quote from BATS)

$5.12 USD

5.12
6,935,868

+1.25 (32.30%)

Updated Aug 6, 2025 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is a Beat in Store for Ionis (IONS) This Earnings Season?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

    Zacks Equity Research

    Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

    by Zacks Equity Research

    Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

      Zacks Equity Research

      Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

      by Zacks Equity Research

      ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

        Zacks Equity Research

        Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?

        by Zacks Equity Research

        Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

          Zacks Equity Research

          Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties

          by Zacks Equity Research

          Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties

            Zacks Equity Research

            Buy 5 Low-Beta Stocks & Forget Market Volatility

            by Zacks Equity Research

            We present a strategy that shows handsome return can be generated from investment in less risky stocks.

              Zacks Equity Research

              Myriad Genetics Presents Favorable riskScore Test Data

              by Zacks Equity Research

              Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.

                Zacks Equity Research

                Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

                by Zacks Equity Research

                Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.

                  Zacks Equity Research

                  Myriad Genetics' EndoPredict Gets Positive Coverage Decision

                  by Zacks Equity Research

                  Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

                    Zacks Equity Research

                    Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

                    by Zacks Equity Research

                    Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                      Zacks Equity Research

                      CVS Health Grows on Specialty Pharmacy amid Retail Woes

                      by Zacks Equity Research

                      CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

                        Zacks Equity Research

                        Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

                        by Zacks Equity Research

                        Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

                          Zacks Equity Research

                          Haemonetics Banks on Solid Plasma & Haemonetics Management

                          by Zacks Equity Research

                          Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

                            Zacks Equity Research

                            Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

                            by Zacks Equity Research

                            Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

                              Zacks Equity Research

                              Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                              by Zacks Equity Research

                              Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                Zacks Equity Research

                                Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?

                                by Zacks Equity Research

                                Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.

                                  Zacks Equity Research

                                  Myriad Genetics to Grow with Study Successes, New Alliances

                                  by Zacks Equity Research

                                  On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).

                                    Zacks Equity Research

                                    Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

                                    by Zacks Equity Research

                                    Myriad Genetics, Inc. (MYGN) moved big last session, as its shares rose over 5% on the day.

                                      Zacks Equity Research

                                      Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive

                                      by Zacks Equity Research

                                      Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.

                                        Zacks Equity Research

                                        Why Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report?

                                        by Zacks Equity Research

                                        Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Zacks Equity Research

                                          Myriad Genetics Gets Extended Coverage for Prolaris Test

                                          by Zacks Equity Research

                                          Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.

                                            Zacks Equity Research

                                            Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View

                                            by Zacks Equity Research

                                            Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.

                                              Zacks Equity Research

                                              Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

                                              by Zacks Equity Research

                                              Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

                                                Zacks Equity Research

                                                Myriad Genetics (MYGN) Launches EndoPredict Test in the US

                                                by Zacks Equity Research

                                                Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.

                                                  Zacks Equity Research

                                                  Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report?

                                                  by Zacks Equity Research

                                                  Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.